Biennial report on genitourinary cancers

European Journal of Cancer

Volumn 66, Issue , 2016, Pages 125-130

  Fizazi, Karim ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Bladder cancer; Germ cell tumors; Prostate cancer; Renal cell cancer; Testicular cancer

Indexed keywords

CABOZANTINIB; DOCETAXEL; NIVOLUMAB; TUMOR MARKER; ANTIANDROGEN; ANTINEOPLASTIC AGENT;

ANDROGEN DEPRIVATION THERAPY; ARTICLE; BIENNIAL PLANT; BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; DNA REPAIR; FOLLOW UP; GENETIC VARIABILITY; GERM CELL TUMOR; HEALTH CARE QUALITY; HUMAN; KIDNEY CANCER; LIFE SUSTAINING TREATMENT; LOCAL THERAPY; MALE; NEXT GENERATION SEQUENCING; PRIORITY JOURNAL; UROGENITAL TRACT CANCER; KIDNEY NEOPLASMS; METASTASIS; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RISK FACTOR; TESTICULAR NEOPLASMS; URINARY BLADDER NEOPLASMS; UROGENITAL NEOPLASMS;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS; HUMANS; KIDNEY NEOPLASMS; MALE; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RISK FACTORS; TESTICULAR NEOPLASMS; URINARY BLADDER NEOPLASMS; UROGENITAL NEOPLASMS;

EID: 84983631382     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2016.06.026     Document Type: Article

References (25)

1. [1] Mason, M.D., Parulekar, W.R., Sydes, M.R., Brundage, M., Kirkbride, P., Gospodarowicz, M., et al. Final report of the intergroup randomized study of combined androgen-deprivation therapy plus radiotherapy versus androgen-deprivation therapy alone in locally advanced prostate cancer. J Clin Oncol 33:19 (2015 Jul 1), 2143–2150.
2. [2] Fosså, S.D., Wiklund, F., Klepp, O., Angelsen, A., Solberg, A., Damber, J.E., et al., The Scandinavian Prostate Cancer Group-7 Investigators. ten- and 15-yr prostate cancer-specific mortality in patients with nonmetastatic locally advanced or aggressive intermediate prostate cancer, randomized to lifelong endocrine treatment alone or combined with radiotherapy: final results of the Scandinavian Prostate Cancer Group-7. Eur Urol, 2016 Mar 26, 10.1016/j.eururo.2016.03.021 pii: S0302–2838(16)00278-5 [Epub ahead of print].
3. [3] Mottet, N., Peneau, M., Mazeron, J.J., Molinie, V., Richaud, P., Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial. Eur Urol 62:2 (2012 Aug), 213–219.
4. [4] Sweeney, C.J., Chen, Y.H., Carducci, M., Liu, G., Jarrard, D.F., Eisenberger, M., et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 373:8 (2015 Aug 20), 737–746.
5. [5] James, N.D., Sydes, M.R., Clarke, N.W., Mason, M.D., Dearnaley, D.P., Spears, M.R., et al., STAMPEDE Investigators. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 387:10024 (2016 Mar 19), 1163–1177.
6. [6] Gravis, G., Boher, J.M., Joly, F., Soulié, M., Albiges, L., Priou, F., et al., GETUG. Androgen deprivation therapy (ADT) plus docetaxel versus adt alone in metastatic non castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 trial. Eur Urol 70:2 (2016 Aug), 256–262.
7. [7] Vale, C.L., Burdett, S., Rydzewska, L.H., Albiges, L., Clarke, N.W., Fisher, D., et al., STOpCaP Steering Group. Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data. Lancet Oncol 17:2 (2016 Feb), 243–256.
8. [8] Fizazi, K., Faivre, L., Lesaunier, F., Delva, R., Gravis, G., Rolland, F., et al. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial. Lancet Oncol 16:7 (2015 Jul), 787–794.
9. [9] Ryan, C.J., Smith, M.R., Fizazi, K., Saad, F., Mulders, P.F., Sternberg, C.N., et al., COU-AA-302 Investigators. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 16:2 (2015 Feb), 152–160.
10. [10] Beer, T.M., Armstrong, A.J., Rathkopf, D.E., Loriot, Y., Sternberg, C.N., Higano, C.S., et al., PREVAIL Investigators. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 371:5 (2014 Jul 31), 424–433.
11. [11] Shore, N.D., Chowdhury, S., Villers, A., Klotz, L., Siemens, D.R., Phung, D., et al. Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study. Lancet Oncol 17 (2016), 153–163.
12. [12] Al Nakouzi, N., Le Moulec, S., Albigès, L., Wang, C., Beuzeboc, P., Gross-Goupil, M., et al. Cabazitaxel remains active in patients progressing after docetaxel followed by novel androgen receptor pathway targeted therapies. Eur Urol 68:2 (2015 Aug), 228–235.
13. [13] Gillessen, S., Omlin, A., Attard, G., de Bono, J.S., Efstathiou, E., Fizazi, K., et al. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Ann Oncol 26:8 (2015 Aug), 1589–1604.
14. [14] Antonarakis, E.S., Lu, C., Wang, H., Luber, B., Nakazawa, M., Roeser, J.C., et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 371:11 (2014 Sep 11), 1028–1038.
15. [15] Robinson, D., Van Allen, E.M., Wu, Y.M., Schultz, N., Lonigro, R.J., Mosquera, J.M., et al. Integrative clinical genomics of advanced prostate cancer. Cell 161:5 (2015 May 21), 1215–1228.
16. [16] Mateo, J., Carreira, S., Sandhu, S., Miranda, S., Mossop, H., Perez-Lopez, R., et al. DNA-repair defects and olaparib in metastatic prostate cancer. N Engl J Med 373:18 (2015 Oct 29), 1697–1708.
17. [17] Daugaard, G., Gundgaard, M.G., Mortensen, M.S., Agerbæk, M., Holm, N.V., Rørth, M., et al. Surveillance for stage I nonseminoma testicular cancer: outcomes and long-term follow-up in a population-based cohort. J Clin Oncol 32:34 (2014 Dec 1), 3817–3823.
18. [18] Kollmannsberger, C., Tandstad, T., Bedard, P.L., Cohn-Cedermark, G., Chung, P.W., Jewett, M.A., et al. Patterns of relapse in patients with clinical stage I testicular cancer managed with active surveillance. J Clin Oncol 33:1 (2015 Jan 1), 51–57.
19. [19] Nichols, C.R., Roth, B., Albers, P., Einhorn, L.H., Foster, R., Daneshmand, S., et al. Active surveillance is the preferred approach to clinical stage I testicular cancer. J Clin Oncol 31:28 (2013 Oct 1), 3490–3493.
20. [20] Fizazi, K., Pagliaro, L., Laplanche, A., Fléchon, A., Mardiak, J., Geoffrois, L., et al. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial. Lancet Oncol 15:13 (2014 Dec), 1442–1450.
21. [21] Albers, P., Albrecht, W., Algaba, F., Bokemeyer, C., Cohn-Cedermark, G., Fizazi, K., et al. Guidelines on testicular cancer: 2015 update. Eur Urol 68:6 (2015 Dec), 1054–1068.
22. [22] Motzer, R.J., Escudier, B., McDermott, D.F., George, S., Hammers, H.J., Srinivas, S., et al., CheckMate 025 Investigators. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373:19 (2015 Nov 5), 1803–1813.
23. [23] Choueiri, T.K., Escudier, B., Powles, T., Mainwaring, P.N., Rini, B.I., Donskov, F., et al., METEOR Investigators. Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med 373:19 (2015 Nov 5), 1814–1823.
24. [24] Choi, W., Porten, S., Kim, S., Willis, D., Plimack, E.R., Hoffman-Censits, J., et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 25:2 (2014 Feb 10), 152–165.
25. [25] Powles, T., Eder, J.P., Fine, G.D., Braiteh, F.S., Loriot, Y., Cruz, C., et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515:7528 (2014 Nov 27), 558–562.